Dexcom, Inc., a leading player in the diabetes care industry, is headquartered in the United States. Founded in 1999, the company has pioneered continuous glucose monitoring (CGM) technology, significantly enhancing diabetes management for patients worldwide. With a strong presence in North America, Europe, and Asia, Dexcom focuses on developing innovative solutions that empower individuals to take control of their health. The company's flagship products, including the Dexcom G6 and G7 CGM systems, offer real-time glucose monitoring with exceptional accuracy and ease of use. These devices are distinguished by their ability to provide users with actionable insights, helping to prevent hypoglycaemic events and improve overall glycaemic control. Dexcom's commitment to innovation has solidified its position as a market leader, recognised for its contributions to diabetes management and patient care.
How does Dexcom's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Dexcom's score of 34 is higher than 87% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Dexcom reported total carbon emissions of approximately 25,291,000 kg CO2e, with emissions distributed across various scopes: 3,403,000 kg CO2e from Scope 1 (including 1,983,000 kg CO2e from mobile combustion and 3,400,000 kg CO2e from stationary combustion), 25,291,000 kg CO2e from Scope 2, and 7,348,000 kg CO2e from Scope 3 (including 5,748,000 kg CO2e from business travel and 1,776,000 kg CO2e from waste generated in operations). In previous years, Dexcom's emissions were as follows: in 2022, they emitted about 13,610,000 kg CO2e (Scope 2) and 1,749,000 kg CO2e (Scope 3); in 2021, emissions included approximately 11,807,000 kg CO2e (Scope 2) and 1,587,000 kg CO2e (Scope 3); and in 2020, they reported 9,371,000 kg CO2e (Scope 2) and 1,257,000 kg CO2e (Scope 3). Dexcom is committed to reducing its carbon footprint, having established near-term targets as part of its climate strategy. While specific reduction targets were not disclosed, the company is actively engaged in sustainability initiatives within the healthcare equipment and supplies sector. As of June 2023, Dexcom has not committed to a net-zero target but continues to work towards significant emissions reductions.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 1,903,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 9,371,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 1,257,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dexcom is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.